Brief: Kancera Initiates Clinical Development Of KAND567 In Ovarian Cancer

Novakand Pharma AB

22/09/2022 08:14

Sept 22 (Reuters) - Kancera AB  KANC.ST :
    * REPORTS CONVINCING PRECLINICAL RESULTS AND DECISION TO
INITIATE
CLINICAL DEVELOPMENT OF KAND567 IN OVARIAN CANCER
    * IS REPORTING NEW RESULTS THAT CONFIRM THAT COMPANY'S
FRACTALKINE-BLOCKING CANDIDATE DRUG MAY INCREASE EFFICACY OF
PLATINUM-BASED CHEMOTHERAPY AND REDUCE TUMOR GROWTH IN ANIMAL
MODELS OF OVARIAN CANCER
    * AS A RESULT, KANCERA HAS MET CRITERIA THAT WERE SET FOR
SCIENTIFIC EVALUATION OF PROJECT
    * DECIDED TO PROCEED IN APPLYING FOR REGULATORY APPROVAL TO
CONDUCT CLINICAL STUDIES OF KAND567 IN OVARIAN CANCER PATIENTS
RELAPSING FROM PLATINUM-BASED CHEMOTHERAPY

Source text for Eikon:  ID:nMFN75l3Vq 
Further company coverage:  KANC.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))